GRADE guidelines: 5. Rating the quality of evidence--publication bias.
By G. Guyatt, Andrew D. Oxman, Victor M. Montori, G. Vist, Regina Kunz, J. Brożek, P. Alonso-Coello, B. Djulbegovic, D. Atkins, Y. Falck-Ytter and 5 more. Journal of Clinical Epidemiology, 2011
1,582 citations recorded by the source corpus.
Subfields: Economics and Econometrics, Statistics and Probability
View Paper: https://www.semanticscholar.org/paper/05001a6f6c8242773aaa951c34360cf65dc7c882
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Economics and Econometrics
- Georgia Salanti
- A. Chaimani
- Julian P. T. Higgins
- Matthias Egger
- Tianjing Li
- C. Del Giovane
- Benjamin Rouse
- Douglas G. Altman
In Statistics and Probability
- A. Chaimani
- Georgia Salanti
- Julian P. T. Higgins
- Tianjing Li
- C. Del Giovane
- Benjamin Rouse
- Matthias Egger
- Adriani Nikolakopoulou
Citations in the corpus
- Systematic review and meta-analysis of psychological therapies for children with chronic pain. (2014, background): “Two authors extracted data and any discrepancies were arbitrated by a third author.”
- Network Meta-Analysis: An Introduction for Clinicians (2016, background): “Publication bias may be suspected if direct evidence comes from a small number of commercially funded studies [32], or based on quantitative assessment using contour-enhanced funnel plots [33].”
- Systematic review of physical activity and health in the early years (aged 0-4 years). (2012, methodology): “Within age groups, at least 2 reviewers (S.C.G., M.E.K., B.W.T., and A.G.L.) independently assessed the quality of the evidence for all of the studies (Guyatt et al. 2011a, 2011b, 2011c, 2011d, 2011e, 2011f, 2011g, 2011h; Balshem et al. 2011).”
- CINeMA: An approach for assessing confidence in the results of a network meta-analysis (2020, background): “• The meta-analysis is based on a small number of positive early findings, for example for a drug newly introduced on the market (as early evidence is likely to overestimate its efficacy and safety) [31].”